Darius Sinkevičius, chairman of the board at the Lithuanian Association of Generic Pharmaceuticals Manufacturers (VGA), explains the main trends impacting the generic pharmaceutical industry in the country as well as the role of off-patent medicines in creating savings for the Lithuanian healthcare system.
Can you give to our international audience an idea of the importance of the Lithuanian Association of Generic Pharmaceuticals Manufacturers (VGA)?
"It bears mentioning that Lithuania has good level of inclusion of new chemical entities into the reimbursement list and, indeed, around 50 new products have been recently included over the last years."
